The data suggest that study participants on 800mg of Flurizan maintained more of their global function and activities of daily living than those on 400mg of Flurizan or than the projected placebo.
The data suggest that during the follow-on period from months 12 to 21, the benefit of Flurizan on the measures of Alzheimer’s disease increases, in terms of both effect size and significance, the longer patients remain on Flurizan.
“The 21 months of data give us further confidence in the power of our phase III trial to demonstrate a benefit from Flurizan for Alzheimer’s patients,” said Dr Adrian Hobden, president of Myriad Pharmaceuticals. “The results are additional evidence that Flurizan appears to be modifying the course of the underlying disease process.”
Flurizan is the first in a new class of drug candidates known as selective amyloid beta-42 lowering agents (SALAs).